急性脑梗死患者30例静脉溶栓联合多模式血管内治疗的围术期护理被引量：19

下载PDF

导出

摘要急性脑梗死治疗目标是使闭塞血管再通和恢复缺血脑组织的再灌注,因此早期救治对预后极其重要.大量研究证实发病时间窗(4.5h)内静脉注射阿替普酶溶栓是首选的治疗方法;然而,能在溶栓时间窗内及时到医院且无禁忌证的患者较少,且对合并颅内大血管重度狭窄或闭塞的患者再通率较低,使得早期血管内治疗越来越受到重视[1].2015年5项国际多中心随机对照研究(RCT)均显示早期给予血管内治疗明显提高了再通率,为这类患者治疗提供新的证据[2].本研究回顾性分析山西医科大学附属第六医院神经内科2016年1月至2018年5月收治的30例急性脑梗死静脉溶栓桥接血管开通治疗的患者的临床资料,现报告如下.

作者焦晋燕

机构地区太原钢铁(集团)有限公司总医院神经内科

出处《中国药物与临床》 CAS 2019年第10期1737-1738,共2页 Chinese Remedies & Clinics

关键词急性脑梗死患者血管内治疗静脉溶栓围术期护理多中心随机对照研究溶栓时间窗多模早期救治

分类号 R473.74 [医药卫生—护理学]

引文网络
相关文献

参考文献3

1Edward C. Jauch,Jeffrey L. Saver,Harold P. Adams,Askiel Bruno,J.J. (Buddy) Connors,Bart M. Demaerschalk,Pooja Khatri,Paul W. McMullan,Adnan I. Qureshi,Kenneth Rosenfield,Phillip A. Scott,Debbie R. Summers,David Z. Wang,Max Wintermark,Howard Yonas,李海峰(译),岳耀先(译),王琦(译),张贤军(译),丁晓君(译).急性缺血性卒中患者早期处理指南：美国心脏协会／美国卒中协会对医疗专业人员的指南（续前）[J].国际脑血管病杂志,2013,21(8):564-605. 被引量：991
2高峰,徐安定.急性缺血性卒中血管内治疗中国指南2015[J].中国卒中杂志,2015,10(7):590-606. 被引量：297
3急性缺血性脑卒中血管内治疗术后监护与管理中国专家共识[J].中华医学杂志,2017,97(3):162-172. 被引量：80

二级参考文献106

1丁宏岩,董强.基底动脉梗死的治疗:动脉和静脉溶栓效果比较的系统分析[J].中国卒中杂志,2006,1(6):414-416. 被引量：127
2Wahlgren N, Ahrced N, Davalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet, 2007, 369: 275-282.
3Lyden PD, ed. Thrombolytic Therapy for Acute Stroke. 2nd ed. Totowa, NJ: Hmreana Press, 2005.
4Wardlaw JM, Smdercock PA, Berg: E. Throrrbolytic therapy with recoinbinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cunaflative meta-analysis. Stroke, 2003, 34: 1437-1442.
5Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2003, (4): CD000213.
6Shanna M, Clark H, Armour T, et al. Acute stroke: evaluation and treatment. Evid Rep Technol Assess (Sunmm), 2005, (127): 1-7.
7Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Throrrbolysis for acute ischemic stroke: results of the Canadian Altephse for Stroke Effectiveness Study. CMAJ, 20(0, 172: 1307-1312.
8Chung H, Refoios Canto R, Canto RR, et al. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart, 2007, 93: 1616-1617.
9Saver JL, Smith EE, Fonarow GC, et al; GWTG-stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in > 30,000 patients ariving within 60 minutes of stroke onset. Stroke, 2010, 41: 1431-1439.
10Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergmcy physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke, 2010, 41: 2026-2032.